Athenex, a US-China cancer biopharma, completed a $66 million IPO on the NASDAQ exchange. Although that was the low end of the expected range, the company's shares have climbed 24% since they began trading. Athenex is developing a two-drug combination that would allow oral administration of common IV chemotherapies. The company is based in Buffalo, New York. It has partnered with New York State officials to build facilities there and with Chongqing to build a China manufacturing plant. It also has an R&D lab in Hong Kong.
Source: ChinaBio Today
Please to leave a comment.